Biohaven Ltd. logo

Biohaven Ltd.(BHVN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 12 days
PROFIT SINCE LAST BUY
-16.19% ▼
LAST CLOSE
$13.82
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BHVN

11/13/2026: BHVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Biohaven Ltd. is a clinical-stage biopharmaceutical company that develops innovative therapies for neurological, psychiatric, and specialty diseases. The company's main strengths lie in its experienced leadership team, broad clinical pipeline, and proprietary platforms targeting conditions with high unmet medical need. Its primary growth story centers on advancing key assets like troriluzole and taldefgrobep alfa toward potential regulatory approvals. Key risks include ongoing operational cash burn, clinical trial execution uncertainty, and intense competition in the neuroscience space. The stock best suits growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical readouts and regulatory catalysts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitBiohaven offers significant upside potential tied to its expansive clinical pipeline and innovative neurology drug candidates.
Momentum investorStrong fit while signal remains positiveClinical trial readouts and regulatory catalysts frequently trigger sharp short-term momentum shifts in the stock price.
Value investorWeak fitThe company currently lacks consistent positive earnings and commercial revenue, making traditional value metrics inapplicable.
Dividend investorWeak fitBiohaven does not pay dividends, directing all cash flow into clinical research and pipeline development.
Low-risk investorWeak fitClinical-stage biotechnology equities experience high volatility driven by binary trial outcomes and regulatory decisions.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock valuations fluctuate sharply based on clinical updates, regulatory feedback, and market sentiment.
Valuation riskMedium / highValuation relies heavily on future drug approvals rather than current earnings or cash flows.
Competition risk (neurology and rare disease therapeutics)HighThe company competes with well-capitalized pharmaceutical firms targeting similar neurological pathways.
Business qualityMediumWhile backed by experienced science teams, the lack of commercialized revenue streams limits current financial depth.
Dividend incomeLow / noneNo dividend distributions are provided to shareholders.
Execution riskHighSuccess depends entirely on executing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.09B USD
Price to earnings Ratio -
1Y Target Price 23.73
Price to earnings Ratio -
1Y Target Price 23.73
Volume (30-day avg) 3.2M shares
Beta 3.13
52 Weeks Range 7.99 - 18.24
Updated Date 11/15/2026
52 Weeks Range 7.99 - 18.24
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.77

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -8.29%
Avg. Invested days 31
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BHVN receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
BHVN has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, solid earnings growth (+12.7%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
BHVN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is BHVN's strongest growth driver at +12.7% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (+0.0%, slightly negative) and free-cash-flow growth (-4.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 94.7% and approximately 77.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 12.46% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.75%
Suvretta Capital Management, LLC 6.81%
Stifel Financial Corp 6.58%
Jupiter Topco LLC 5.68%
Woodline Partners LP 5.07%

Unit Economics (Per $1K Revenue)

★★★★★
BHVN generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.20% (Tax Credit)

Quantitative Style Profile

★★★★★
BHVN has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development and LicensingPotential milestone payments, collaborative research agreements, and future commercial sales of approved drug candidates.Biohaven is currently a pre-commercial development company aiming to generate future revenue from successful drug approvals.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2.23B
Price to Sales(TTM) -
Enterprise Value 2.23B
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.19
Shares Outstanding 151.06M
Shares Floating 116.59M
Shares Outstanding 151.06M
Shares Floating 116.59M
Percent Insiders 12.46
Percent Institutions 94.72

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.